IL-6 receptor antagonists and antiplatelet agents improve survival among critically ill COVID-19 patients
Patients who are critically ill with COVID-19 infection had a 99.9% probability of improved 180-day mortality compared to placebo when treated with IL-6 receptor antagonist and a 95.0% probability of improved 180-day mortality when on antiplatelets compared to control. The trial results of the REMAP-CAP Randomized Clinical Trial were published in the journal JAMA Network.
Randomized clinical trials in critically ill patients, even those with COVID-19, typically assess only short-term outcomes like organ failure or 28-day mortality. Still, there is uncertainty regarding the longer-term effects of therapies used for the treatment of critically ill patients with COVID-19. Hence researchers conducted a secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) to determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes between March 9, 2020, and June 22, 2021.
Nearly 4869 critically ill adult patients with COVID-19 with a mean age of 59.3 years (1537 [32.1%] women) were enrolled for testing interventions within multiple therapeutic domains. Patients were randomized to receive 1 or more interventions within 6 treatment domains like the immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). A Bayesian outcome was survival through day 180. Bayesian piecewise exponential model was used to analyze this. Survival was measured by Hazard ratio where <1 meant improved survival (superiority) and > 1 meant worsened survival (harm). A relative improvement of less than 20% in outcome, shown by an HR greater than 0.83 represented futility.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.